Evidence map›Paper›PMID 31863077›Full record

ArticleNature protocols2020

Sequential phosphoproteomics and N-glycoproteomics of plasma-derived extracellular vesicles.

Hillary Andaluz Aguilar, Anton B Iliuk, I-Hsuan Chen, W Andy Tao

Open access · greenAbstract read
In one paragraph

Article in Nature protocols, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
3.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 98 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Plasma-Derived Extracellular Vesicle Proteomics.Journal of proteome research · 2025
    Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Hillary Andaluz AguilarDepartment of Chemistry, Purdue University, West Lafayette, IN, USA.
Anton B IliukTymora Analytical Operations, West Lafayette, IN, USA.
I-Hsuan ChenDepartment of Biochemistry, Purdue University, West Lafayette, IN, USA.
W Andy TaoDepartment of Chemistry, Purdue University, West Lafayette, IN, USA. watao@purdue.edu.
Purdue University West Lafayette · USTymora Analytical Operations (United States) · US

Funding

New Proteomic Technologies for the Analysis of Tyrosine Kinase Signaling PathwaysR01GM088317 · NIGMS · PURDUE UNIVERSITY · PI TAO, W. ANDY · 2010 to 2014
$1.6M
Development of non-invasive biomarker discovery and diagnostics approach for bladder cancer based on urine proteome and phosphoproteomeR44CA239845 · NCI · TYMORA ANALYTICAL OPERATIONS, LLC · PI ILIUK, ANTON · 2019 to 2021
$1.5M
A Proteomic Platform to identify and Validate Biomarkers in Metabolic Syndrome and Coronary Artery DiseaseR01GM111788 · NIGMS · PURDUE UNIVERSITY · PI TAO, W. ANDY · 2015 to 2017
$900k
Developing EV surface proteins as biosignatures for Alzheimer's disease (AD)R41AG066328 · NIA · TYMORA ANALYTICAL OPERATIONS, LLC · PI TAO, W. ANDY · 2020 to 2020
$245k
Development of non-invasive research and diagnostics platform for Alzheimer's disease based on plasma exosomesR43AG063589 · NIA · TYMORA ANALYTICAL OPERATIONS, LLC · PI ILIUK, ANTON · 2019 to 2019
$215k
NCI NIH HHS R44 CA239845NIA NIH HHS R41 AG066328NIA NIH HHS R43 AG063589NIGMS NIH HHS R01 GM088317NIGMS NIH HHS R01 GM111788
6 · The paper itself

Abstract

Extracellular vesicles (EVs) are increasingly being recognized as important vehicles for intercellular communication and as promising sources for biomarker discovery. Because the state of protein post-translational modifications (PTMs) such as phosphorylation and glycosylation can be a key determinant of cellular physiology, comprehensive characterization of protein PTMs in EVs can be particularly valuable for early-stage diagnostics and monitoring of disease status. However, the analysis of PTMs in EVs has been complicated by limited amounts of purified EVs, low-abundance PTM proteins, and interference from proteins and metabolites in biofluids. Recently, we developed an approach to isolate phosphoproteins and glycoproteins in EVs from small volumes of human plasma that enabled us to identify nearly 10,000 unique phosphopeptides and 1,500 unique N-glycopeptides. The approach demonstrated the feasibility of using these data to identify potential markers to differentiate disease from healthy states. Here we present an updated workflow to sequentially isolate phosphopeptides and N-glycopeptides, enabling multiple PTM analyses of the same clinical samples. In this updated workflow, we have improved the reproducibility and efficiency of EV isolation, protein extraction, and phosphopeptide/N-glycopeptide enrichment to achieve sensitive analyses of low-abundance PTMs in EVs isolated from 1 mL of plasma. The modularity of the workflow also allows for the characterization of phospho- or glycopeptides only and enables additional analysis of total proteomes and other PTMs of interest. After blood collection, the protocol takes 2 d, including EV isolation, PTM/peptide enrichment, mass spectrometry analysis, and data quantification.

Indexed as

Extracellular VesiclesGlycoproteinsHumansPhosphoproteinsPlasmaProtein Processing, Post-TranslationalProteomicsGlycoproteinsPhosphoproteins

Identifiers

PMID31863077
PMCPMC7194202
OpenAlexW2996274474

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.